Avidity Biosciences
About: Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Employees: 391
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 76
0% more ownership
Funds ownership: 106.96% [Q3] → 106.96% (+0%) [Q4]
4% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 51
6% less call options, than puts
Call options by funds: $19.5M | Put options by funds: $20.9M
3% less funds holding
Funds holding: 242 [Q3] → 234 (-8) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 8 (-2) [Q4]
35% less capital invested
Capital invested by funds: $5.75B [Q3] → $3.71B (-$2.04B) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
HC Wainwright & Co. Andrew Fein 29% 1-year accuracy 98 / 337 met price target | 124%upside $68 | Buy Maintained | 12 May 2025 |
Chardan Capital Keay Nakae 16% 1-year accuracy 12 / 76 met price target | 114%upside $65 | Buy Maintained | 9 May 2025 |
Needham Joseph Stringer 25% 1-year accuracy 25 / 102 met price target | 98%upside $60 | Buy Reiterated | 9 Apr 2025 |
Citigroup Geoff Meacham 36% 1-year accuracy 12 / 33 met price target | 131%upside $70 | Buy Initiated | 13 Mar 2025 |
BMO Capital Kostas Biliouris 7% 1-year accuracy 1 / 15 met price target | 137%upside $72 | Outperform Initiated | 12 Mar 2025 |
Financial journalist opinion
Based on 4 articles about RNA published over the past 30 days









